Trace Medicine has launched with $101 million in series A funds and a mission to treat amyotrophic lateral sclerosis (ALS) by targeting the same protein that recently caught the attention of Eli ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Trace Neuroscience launched on Tuesday to announce that it is developing a genetic treatment targeting UNC13A, a gene linked to both a higher risk of ALS and faster disease progression.